Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31517932 | 1.00 | CYP2D6 (0.38) | CYP2D6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL9510438 | 0.90 | KDM4E (0.39) | CYP2D6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL621079 | 0.81 | KMT2A (0.33) | KDM4EKMT2AHSD17B10 | |
| SCHEMBL10833113 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL10832554 | 0.75 | ALDH1A1 (0.39) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL9698419 | 0.74 | CYP2D6 (0.40) | CYP2D6KDM4EALDH1A1GAAMAPT | |
| SCHEMBL10405096 | 0.74 | ALDH1A1 (0.39) | CYP2D6KDM4EALDH1A1HPGD | |
| SCHEMBL8560743 | 0.73 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTNPC1MEN1 | |
| SCHEMBL9877944 | 0.73 | KDM4E (0.38) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL8560748 | 0.73 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719603-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| CN-119998271-A | Pyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| EP-4511117-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250019385-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-01-16 | — | — | US | disclosed |
| WO-2024246099-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-05 | — | — | WO | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3256450-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| US-5607936-A | USEFUL IN TREATMENT OF RESPIRATORY DISEASES | MERCK & CO., INC. (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996010568-A1 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1996-04-11 | — | — | WO | disclosed |
| EP-0276057-B1 | Piperazinylpyrimidines as beta-adrenergic receptor blocking agents | MERCK & CO INC (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5064826-A | Analgesic, antiderpressant | EGIS GYOGYSZERGYAR (HU) | 1991-11-12 | — | — | US | disclosed |
| US-4994464-A | Treatment of elevated intraocular pressure and glaucoma | MERCK & CO., INC. (US) | 1991-02-19 | — | — | US | disclosed |
| US-4889856-A | INTRAOCULAR PRESSURE REDUCTION; CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1989-12-26 | — | — | US | disclosed |
| US-4871739-A | Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents | MERCK & CO., INC. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0276057-A2 | Piperazinylpyrimidines as beta-adrenergic receptor blocking agents | MERCK & CO. INC. (US) | 1988-07-27 | — | — | EP | disclosed |
| US-4578378-A | (Oxoheterocyclic carbonamido)cephem carboxylic acid derivatives | SHIONOGI & CO., LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
| US-4435566-A | HYPOGLYCEMIA, ANTIHISTAMINE, ANTIDIABETIC ACTIVITY | MARUKO SEIYAKU CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019385-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, RB1 | CYP2D6 191/4885KDM4E 2557/4885ALDH1A1 1084/4885 |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | CYP2D6 259/4885KDM4E 4567/4885ALDH1A1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.